An observational study in Ovarian Cancer, sponsored by Yonsei University. Recruiting at 1 site in Korea, Republic of. Open to female participants aged 19 Years to 85 Years. Per ClinicalTrials.gov, last updated 2022-12-07.
Sponsored by Yonsei University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Ovarian Neoplasms by Yonsei University — 4 open to participants now, 6 under way, none of them phase 3. Ovarian Neoplasms · Yonsei University.
Among the 14 studies in Ovarian Neoplasms by Yonsei University, this one is the only one that started in 2022, is one of 5 observational ones, and was the 10th registered.
3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.
Browse Ovarian Neoplasms studies →4 of the 14 studies in Ovarian Neoplasms by Yonsei University are open now, in 1 country. Recruiting first, the newest first:
Yonsei University · Sites in Korea, Republic of
Ages 18+ · Women only
Yonsei University · Sites in Korea, Republic of
Ages 19+ · Healthy volunteers
Yonsei University
Ages 19–75 · Women only
By country, each count listing its studies:
Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.
This study: 19 Years to 85 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 54 is below the median of 200 across 617 observational studies indexed under Ovarian Neoplasms.
Median enrollment 44 across the 9 interventional studies, 100 across the 5 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Yonsei University is the lead sponsor of 1,421 studies on the registry; 241 are open to participants now.
2 of the studies in Ovarian Neoplasms by Yonsei University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07340164Yonsei UniversityTrastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy | 2026-12-30 |
| NCT06023862Yonsei UniversityA Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study) | 2027-08-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Ovarian Neoplasms by Yonsei University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Increasing number of ovarian cancer patients are receiving PARP inhibitor as maintenance therapy. Predictive factors to PARP inhibitor other than BRCA mutation or HRD status are unknown. Previous study, we analyzed the dynamic immunological changes in peripheral T cells during PARP inhibitor maintenance therapy and found predictive biomarkers. The purpose of this study is to prospectively validate the biomarkers for predicting response to PAPR inhibitors in ovarian cancer. We collect serial blood samples (before initiation of therapy and after 1, 3, and 6 months) in ovarian cancer patients who receive PARP inhibitor and analyze immunological characteristics of peripheral CD8 and regulatory T cells. Through assessment of the baseline properties and dynamic changes in T cells, we aim to validate the predictive biomarker and develope promising novel targets to enhancing survival outcomes of high-risk patients.
Ovarian cancer patients who receive PARP inhibitor
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Validation of biomarkers for predicting response to PAPR inhibitor
Investigators will utilize baseline peripherap blood mononuclear cells (PBMCs) to validate predictive biomarkers to PARP inhibitor. Response to PAPR inhibitor was defined by BRCA1/2 status and duration of PAPR inhibitor treatment.
Time frame: The primary endpont will be accessed 12 months after last patient registration.
Identify dynamic immunological changes during PAPR inhibitor therapy
Investigators will utilize serial samples to identify dynamic immunological changes during PAPR inhibitor therapy.
Time frame: Immunological changes (Time Frame: 6 months
Identify promising novel targets to enhance survivla outcomes of high-risk pateints in PAPR inhibitor therapy.
Investigators will utilize serial samples to identify dynamic immunological changes during PAPR inhibitor therapy.
Time frame: Identify promising novel targets (Time Frame: 12 months)
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2022 (actual). Primary completion is estimated for Oct 2025, 35 months after the start.
Of 216 non-industry observational studies under Ovarian Neoplasms, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 206. This study's planned 35 months is below that.
Counting every sponsor, half of 268 studies reached it within 61 months; a quarter within 35 and three quarters within 185.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.